Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.
about
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathwayEffectiveness and safety profile of S-1-based chemotherapy compared with capecitabine-based chemotherapy for advanced gastric and colorectal cancer: A meta-analysis.Ethanol-mediated regulation of cytochrome P450 2A6 expression in monocytes: role of oxidative stress-mediated PKC/MEK/Nrf2 pathway.Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patientsPhase II multi-center clinical study on using S-1 to treat advanced breast cancer after resistance to anthracycline and taxane drugs in Chinese patientsS-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysisDose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer.A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysisGastric cancer pharmacogenetics: progress or old tripe?p16 Methylation is associated with chemosensitivity to fluorouracil in patients with advanced gastric cancer.Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.Variation in CYP2A6 Activity and Personalized Medicine.
P2860
Q27012807-2D12DD8F-9279-4F66-B57A-20FBC75EAAF0Q30834530-E987878E-79F4-44B3-A717-4D551FD076D8Q33415971-E5685758-A4DE-48F9-A133-F2ED4DB10669Q34243809-27F7B059-8379-4460-8C71-5737DBFBBA7DQ34627947-5CF22B4C-7191-4024-A6AD-0704813A9961Q34745772-A8AD8635-5711-4E24-867B-59EFBA1E424CQ35482173-1090575B-BCAF-4B35-8931-B93BF79AB02DQ37182236-ACC1E029-F284-4638-B504-95727E3FC68DQ37561374-46D7545D-B9F7-4A05-B0DC-1C490D8939CDQ37724706-CD2BB6BA-FF3B-46C5-9F34-E24C0679D36DQ38120288-34451C8F-2577-4FB4-8F8A-8D294942C059Q39194676-54845FF3-4717-4DEC-8497-E5EBC888B529Q44150769-CB6ABEDE-1F56-4702-889C-0467F31FEC96Q47163198-F4B7675C-872D-4B79-AE5B-8AEB887B02F2
P2860
Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Association of CYP2A6 polymorp ...... in metastatic gastric cancer.
@en
Association of CYP2A6 polymorp ...... in metastatic gastric cancer.
@nl
type
label
Association of CYP2A6 polymorp ...... in metastatic gastric cancer.
@en
Association of CYP2A6 polymorp ...... in metastatic gastric cancer.
@nl
prefLabel
Association of CYP2A6 polymorp ...... in metastatic gastric cancer.
@en
Association of CYP2A6 polymorp ...... in metastatic gastric cancer.
@nl
P2093
P2860
P356
P1433
P1476
Association of CYP2A6 polymorp ...... in metastatic gastric cancer.
@en
P2093
Byung-Ho Nam
Hyeong-Seok Lim
Il Ju Choi
Jin Soo Lee
Jun Ho Lee
Keun Won Ryu
Myeong-Cherl Kook
Noe Kyeong Kim
Sook Ryun Park
Sun-Young Kong
P2860
P304
P356
10.2217/PGS.09.48
P577
2009-07-01T00:00:00Z